Axe Microbiologie-Infectiologie et Immunologie, CHU de Québec-Université Laval, Québec, QC, Canada.
Service d'allergie, CHU de Québec-Université Laval, Québec, QC, Canada.
Front Immunol. 2018 Oct 2;9:2183. doi: 10.3389/fimmu.2018.02183. eCollection 2018.
Multiple pathways have been proposed to generate bradykinin (BK)-related peptides from blood. We applied various forms of activation to fresh blood obtained from 10 healthy subjects or 10 patients with hereditary angioedema (HAE-1 or -2 only) to investigate kinin formation. An enzyme immunoassay for BK was applied to extracts of citrated blood incubated at 37°C under gentle agitation for 0-2 h in the presence of activators and/or inhibitory agents. Biologically active kinins in extracts were corroborated by c-Fos accumulation in HEK 293a cells that express either recombinant human B or B receptors (BR, BR). Biological evidence of HAE diagnostic and blood cell activation was also obtained. The angiotensin converting enzyme inhibitor enalaprilat, without any effect , increased immunoreactive BK (iBK) concentration under active stimulation of blood. Tissue kallikrein (KLK-1) and Kontact-APTT, a particulate material that activates the contact system, rapidly (5 min) and intensely (>100 ng/mL) induced similar iBK generation in the blood of control or HAE subjects. Tissue plasminogen activator (tPA) slowly (≥1 h) induced iBK generation in control blood, but more rapidly and intensely so in that of HAE patients. Effects of biotechnological inhibitors indicate that tPA recruits factor XIIa (FXIIa) and plasma kallikrein to generate iBK. KLK-1, independent of the contact system, is the only stimulus leading to an inconsistent BR stimulation. Stimulating neutrophils or platelets did not generate iBK. In the HAE patients observed during remission, iBK formation capability coupled to BR stimulation appears largely intact. However, a selective hypersensitivity to tPA in the blood of HAE patients suggests a role of plasmin-activated FXIIa in the development of attacks. Proposed pathways of kinin formation dependent on blood cell activation were not corroborated.
已经提出了多种途径来从血液中生成缓激肽(BK)相关肽。我们应用各种形式的激活方法,对来自 10 名健康受试者或仅 10 名遗传性血管水肿(HAE-1 或 -2)患者的新鲜血液进行处理,以研究激肽的形成。应用酶免疫分析法对枸橼酸盐血液提取物进行检测,这些提取物在 37°C 下于温和搅拌下孵育 0-2 小时,存在激活剂和/或抑制剂。提取物中的生物活性激肽通过表达重组人 B 或 B 受体(BR,BR)的 HEK 293a 细胞中的 c-Fos 积累得到证实。还获得了 HAE 诊断和血细胞激活的生物学证据。血管紧张素转换酶抑制剂依那普利拉特(enalaprilat)在血液的积极刺激下没有任何作用,但增加了免疫反应性 BK(iBK)的浓度。组织激肽释放酶(KLK-1)和 Kontact-APTT,一种激活接触系统的颗粒物质,迅速(5 分钟)和强烈(>100ng/mL)诱导对照或 HAE 受试者血液中产生类似的 iBK。组织纤溶酶原激活物(tPA)在对照血液中缓慢(≥1 小时)诱导 iBK 的产生,但在 HAE 患者的血液中更快且更强烈。生物技术抑制剂的作用表明,tPA 募集因子 XIIa(FXIIa)和血浆激肽释放酶来生成 iBK。KLK-1 独立于接触系统,是唯一导致 BR 刺激不一致的刺激物。刺激中性粒细胞或血小板不会产生 iBK。在观察到的缓解期 HAE 患者中,与 BR 刺激相关的 iBK 形成能力似乎基本完整。然而,HAE 患者血液中对 tPA 的选择性高敏性提示纤溶酶激活的 FXIIa 在发作的发展中起作用。依赖于血细胞激活的激肽形成途径未得到证实。